Pharmaceuticals News

PALO ALTO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on...

Investor Conference participation

Decoy Therapeutics reports Q3 2026 progress, including an optimized pan-coronavirus lead with once-weekly dosing potential and $8.1 million in cash.

Ron Renaud, President and Chief Executive Officer, and additional members of the management team will participate in the following investor conferences

NEW HAVEN, Conn., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on November 1, 2026, Invivyd granted seven newly hired non-executive employees options to...

CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with...

Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference

FREDERICK, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune...

Cambridge, Massachusetts, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting...

COMPANY STRENGTHENS NEUROSCIENCE LEADERSHIP WITH WELTRUZA™ LAUNCH AND STRATEGIC ADDITION OF BXCL-501 Q3 2026 revenues of $4.4 billion, a decrease of 2% year-over-year in both U.S. dollars and local...